By in , , , ,

INTERVIEW: Sativa Investments – PhytoVista Market Leading in capability and turnaround times

Sativa Investments (NEX: SATI) CEO Geremy Thomas talks to DirectorsTalk about having completed its 1000th cannabinoid and terpenes test at its on-site testing facility, PhytoVista Laboratories. Geremy explains the types of tests, the significance of passing this milestone, ISO accreditation and planning for a larger market share.

Sativa Investments PLC, the UK’s first medicinal cannabis investment vehicle, announced that it has completed its 1000th cannabinoid and terpenes test at its on-site testing facility, PhytoVista Laboratories. The increased growth of the CBD industry in the UK has led to a rise in the demand for high-quality testing and batch certification, with PhytoVista being a leading service provider.

PhytoVista has state-of-the-art equipment to enable testing for pesticides, heavy metals, residual solvents, cannabinoids, terpenes and mycotoxins. The laboratory is able to certify that products and samples conform to regulatory standards. Turnaround time is usually five days or less. It is believed to be the only testing facility in the UK to focus on CBD and it also intends to test medicinal cannabis products once its relevant Home Office handling licences are granted.

PhytoVista also announces the recruitment of an analytical chemist and a microbiologist to expand capacity and also to operate a bespoke micro laboratory which is under construction and nearing completion. PhytoVista’s Chief Scientific Officer, Nick Clarkson, is developing additional testing methods and the Company is in the process of obtaining ISO 17025 accreditation. PhytoVista is already operating to ISO 17025 at present.

Nick was a keynote speaker at the Future Cannabis Strategies event in London in January 2019, where PhytoVista was also co-sponsor. PhytoVista also exhibited at the Hemp & CBD Expo this March in Birmingham. PhytoVista will also be at the Europe CBD Expo in London this June to showcase its testing facility.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said:

“The Company is fulfilling what it has set out to do through its holistic seed-to-consumer strategy and reaching its 1000th test is an early milestone. The laboratory can test the full spectrum of cannabinoid profiles and terpene content, from CBD wellness products to e-liquids, beer, chocolate and toothpaste.”

“PhytoVista is also a key part of Sativa’s internal strategic development as having an in-house, on-site testing facility is assisting the Company’s Home Office Research Licence application. The laboratory is also attracting significant interest from the pharmaceutical and academic research arenas which need an independent testing facility that mandates Good Laboratory Practice to verify and validate their own findings.

By in

Sativa’s PhytoVista Laboratories’ 1000th cannabinoid and terpenes test and two new hires

Sativa Investments

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

  (“Sativa” or “the Company”)

 Sativa’s PhytoVista Laboratories’ 1000th cannabinoid and terpenes test and two new hires

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has completed its 1000thcannabinoid and terpenes test at its on-site testing facility, PhytoVista Laboratories (“PhytoVista”).  The increased growth of the CBD industry in the UK has led to a rise in the demand for high-quality testing and batch certification, with PhytoVista being a leading service provider. 

PhytoVista has state-of-the-art equipment to enable testing for pesticides, heavy metals, residual solvents, cannabinoids, terpenes and mycotoxins.  The laboratory is able to certify that products and samples conform to regulatory standards.  Turnaround time is usually five days or less.  It is believed to be the only testing facility in the UK to focus on CBD and it also intends to test medicinal cannabis products once its relevant Home Office handling licences are granted. 

PhytoVista also announces the recruitment of an analytical chemist and a microbiologist to expand capacity and also to operate a bespoke micro laboratory which is under construction and nearing completion.  PhytoVista’s Chief Scientific Officer, Nick Clarkson, is developing additional testing methods and the Company is in the process of obtaining ISO 17025 accreditation. PhytoVista is already operating to ISO 17025 at present. 

Nick was a keynote speaker at the Future Cannabis Strategies event in London in January 2019, where PhytoVista was also co-sponsor. PhytoVista also exhibited at the Hemp & CBD Expo this March in Birmingham.  PhytoVista will also be at the Europe CBD Expo in London this June to showcase its testing facility. 

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “The Company is fulfilling what it has set out to do through its holistic seed-to-consumer strategy and reaching its 1000thtest is an early milestone.  The laboratory can test the full spectrum of cannabinoid profiles and terpene content, from CBD wellness products to e-liquids, beer, chocolate and toothpaste. 

“PhytoVista is also a key part of Sativa’s internal strategic development as having an in-house, on-site testing facility is assisting the Company’s Home Office Research Licence application.  The laboratory is also attracting significant interest from the pharmaceutical and academic research arenas which need an independent testing facility that mandates Good Laboratory Practice to verify and validate their own findings.” 

The Directors of the Company accept responsibility for the contents of this announcement. 

From left to right: Nick Clarkson (Chief Scientific Officer) and Rob McMahon (Analytical Chemist) in the state of the art Laboratory

–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

gm@peterhousecap.com

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark

Abchurch Switchboard

SativaInvestments@abchurch-group.com

 

+44 (0) 20 7469 4633 

 

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

 

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option ona 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativagroup.co.uk